Ferring Pharmaceuticals
Privately owned Swiss biopharmaceutical leader specialising in reproductive medicine, maternal health, and specialty therapeutics.
Ferring Pharmaceuticals Annual Report 2024Ferring Pharmaceuticals is a privately held, research-driven specialty biopharmaceutical group founded in 1950 by Dr. Frederik Paulsen Sr. and Dr. Eva Paulsen in Malmö, Sweden. Its global headquarters are in Saint-Prex, Switzerland, and it has remained family-controlled since its founding, giving it a long-term R&D orientation uncommon among companies of its scale.
The company employs over 7,000 people, operates subsidiaries in more than 50 countries, and markets its products in over 100 countries. Ferring is recognised as a global leader in reproductive medicine and maternal health, with a broader therapeutic footprint spanning gastroenterology, urology, uro-oncology, and orthopaedics. It also holds a distinguished scientific heritage as the first company to synthesise peptides into drugs for treating endocrine-based disorders.
Key products include Rekovelle, LutrePulse, and Menopur (infertility), Pabal (postpartum), and Firmagon/Degarelix (prostate cancer). In 2022, Ferring secured two landmark FDA approvals: Rebyota, the first FDA-approved fecal microbiota product for recurrent C. diff prevention, and Adstiladrin, a first-in-class gene therapy. U.S. sales exceeded €1 billion for the first time in 2024, representing 48% of total sales per Ferring's 2024 Annual Report.
Given its deep focus on reproductive health, maternal medicine, and pioneering biologics and gene therapies, Ferring is highly relevant to innovations in fertility treatment, microbiome therapeutics, and specialty drug development.